Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Many cancer therapies achieve durable control without complete tumor eradication, suggesting that disrupting tumor organization may be more critical than killing cells. We propose that effective treatments converge by destabilizing the tumor’s Group Phenotypic Composition (GPC), the functional and spatial organization of interacting cell populations. When this organization collapses, tumors lose coherence.
Highlights • Provide update clinical recommendations for BRCA testing for preventive purpose. • Offer testing clinical guidelines for personalised management of early and metatstatic breast cancer. • Actualize germline and tumor testing indications for PARPi-approved therapies. • Address the issues of rapid process and tumor analysis.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. We thank Dr P. Baas et al for their letter.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
